ICU Medical, Inc.
ICUI today announced that two new studies presented this week at the
37^th Annual Association of Pediatric Hematology/Oncology Nurses (APHON)
Annual Conference in Louisville, KY showed that the company's ChemoClave^®
closed system and closed system transfer device (CSTD) improves patient and
clinician safety by reducing hazardous drug exposure and eliminating
accidental needlesticks.
The studies were performed by clinicians at two major children's hospitals—The
Center for Cancer and Blood Disorders at Children's National Medical Center in
Washington DC, and Cook Children's Medical Center (CCMC) in Fort Worth, TX—who
will be available to discuss their findings at the ICU Medical booth (#205) at
the APHON conference.
In the study titled Reducing Hazardous Drug Exposure: Are All Closed Systems
Created Equal? a research team from Children's National Medical Center
reported on an initiative to reduce hazardous drug spills, blood exposure, and
the risks associated with an open central venous catheter caused when a CSTD
disconnects from a patient's IV tubing. The initiative was begun following "a
dramatic rise in exposure to antineoplastic agents due to spills as a direct
result of disconnections of the infusion tubing to the CSTD." (PhaSeal^TM,
Beccton, Dickenson, and Company).
The safety improvement process was implemented in two phases. The first phase
involved assembling an interdisciplinary team to identify the root cause of
hazardous drug spills during patient administration. This team evaluated
incident report data and consulted with PhaSeal CSTD manufacturer
representative. Subsequent practice changes were instituted, and both nursing
and pharmacy teams were reeducated. The outcomes of these changes were
recorded and analyzed.
During the second phase, the interdisciplinary team researched alternative
CSTD systems, including the ICU Medical ChemoClave needlefree CSTD, featuring
the Spinning Spiros^® closed male luer. The team conducted a trial of the
system in June 2012, and implemented the product in November 2012.
In spite of efforts to reduce disconnects with the existing PhaSeal product,
there continued to be disconnects on a regular basis, the researchers
reported. After research and a product trial were completed, the team at
Children's National Medical Center introduced and implemented the ChemoClave
needlefree CSTD featuring the Spinning Spiros in November 2012. To date, there
have been no exposures to hazardous drugs from disconnects following the
conversion to the ChemoClave system.
"The Spiros closed male luer proved to be an effective solution for reducing
disconnects and the potential for dangerous exposure to hazardous drugs and
blood, and complications related to an open line," the researchers concluded,
adding that the Spiros' "small size is ideal for our pediatric patients,
increasing patient/family satisfaction."
In the study titled Improving Chemotherapy Safety via Use of ChemoClave^®
System (Spiros^®), Priming Technique, DoseEdge™, and Volutrols, researchers
from Cook Children's Medical Center took a multi-faceted approach to safety
improvement aimed at reducing exposure to hazardous drugs during both pharmacy
preparation and patient administration. In order to decrease the potential for
aerosolization and leaks of dangerous chemotherapy drugs, CCMC implemented the
ChemoClave CSTD, which included the Spiros closed male luer, needlefree vial
access devices and bag spikes, and administration devices.
To facilitate the effective implementation of ChemoClave, ICU Medical provided
in-servicing for both pharmacy and nursing staff and worked to create a custom
administration set with a pre-bonded Spiros. ChemoClave made it possible for
CCMC staff to prime tubing under the compounding hood, helping to minimize the
risk of chemotherapy aerosolization and surface contamination in the
medication room, while also decreasing the risk of microbial contamination of
the patient line. In addition to the ChemoClave system, CCMC initiated a
variety of practice changes including priming with chemotherapy drugs,
utilizing the DoseEdge™ pharmacy system, and using volutrols for time-limited
infusions.
As a result of these efforts, CCMC has not experienced any events related to
chemotherapy leaks since February 2012. Following additional process changes
in chemotherapy drug preparation and administration, overall central line
associated bloodstream infection rates for the Hematology/Oncology and Stem
Cell Transplant units decreased from 5.8 per 1,000 catheter days in 2009 to
1.6 per 1,000 catheter days in 2012.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in